Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

KRAS mutation status is established as a predictive biomarker of benefit from anti-EGFr therapies. Mutations are normally assessed using DNA extracted from one formalin-fixed, paraffin-embedded (FFPE) tumor block. We assessed heterogeneity of KRAS and BRAF mutation status intra-tumorally (multiple b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Anal Cell Pathol (Amst)
Auteurs principaux: Richman, Susan D., Chambers, Philip, Seymour, Matthew T., Daly, Catherine, Grant, Sophie, Hemmings, Gemma, Quirke, Philip
Format: Artigo
Langue:Inglês
Publié: IOS Press 2011
Sujets:
Other
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605581/
https://ncbi.nlm.nih.gov/pubmed/21483104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/ACP-2011-0005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires